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Abstract 28 
 29 
Objectives: To document the closure rate, safety and stroke rate after thoracoscopic left atrial 30 
appendage (LAA) clipping. 31 
Background: The LAA is the main source of stroke in patients with AF and thoracoscopic clipping 32 
may provide a durable and safe closure technique.  33 
Methods: We studied consecutive patients undergoing clipping as part of a thoracoscopic maze 34 
procedure in 4 referral centers (Netherlands and USA; 2012-2016). Completeness of LAA closure was 35 
assessed by either computed tomography (n=100) or transesophageal echocardiography (n=122). 36 
The primary outcome was complete LAA closure (absence of residual LAA flow and pouch <10 mm). 37 
Secondary outcomes were 30-day complications; the composite of ischemic stroke, hemorrhagic 38 
stroke or transient ischemic attack (TIA); and all-cause mortality. 39 
Results: 222 Patients were included, with a mean age of 66±9 years and 68.5% male. The mean 40 
CHA2DS2-VASc score was 2.3±1.0. Complete LAA closure was achieved in 95.0% of patients. There 41 
were no intraoperative or clip-related complications and the overall 30-day freedom from any 42 
complication was 96.4%. Freedom from cerebrovascular events after surgery was 99.1% after median 43 
follow-up of 20 months (interquartile range 14-25; 369 patient-years of follow-up) and overall survival 44 
was 98.6%. The observed rate of cerebrovascular events after LAA clipping was low (0.5 per 100-45 
patient-years). 46 
Conclusions: LAA clipping during thoracoscopic ablation is a feasible and safe technique for closure 47 
of the LAA in patients with AF. The lower than expected rate of cerebrovascular events after 48 
deployment was likely multifactorial, including not only LAA closure, but also the effect of oral 49 
anticoagulation and rhythm control.  50 
 51 
Keywords: atrial fibrillation; left atrial appendage; left atrial appendage closure; thoracoscopic; stroke; 52 
outcomes   53 
  54 
Condensed Abstract (100 words) 55 
Our objective was to provide cardiologists, surgeons and the multidisciplinary atrial fibrillation (AF) 56 
team with adequate information about thoracoscopic left atrial appendage (LAA) clipping in order to 57 
make appropriate decisions on stroke prevention. We studied 222 consecutive patients undergoing 58 
clipping as part of a thoracoscopic ablation procedure (TT-maze) in 4 referral centers. We observed 59 
high LAA closure rates (95.0%) without clip related complications, high overall 30-day freedom from 60 
any complication (96.4%) and a low stroke rate (0.5 per 100-patient-years). This suggest that 61 
thoracoscopic LAA clipping is a feasible and safe technique for closure of the LAA in patients with AF. 62 
 63 
Abbreviations 64 
AF: atrial fibrillation 65 
CT: computed tomography 66 
LA: Left atrium/left atrial 67 
LAA: left atrial appendage 68 
NOAC: non-vitamin-K-dependent oral anticoagulants 69 
TEE: transesophageal echocardiography 70 
TIA: transient ischemic attack  71 
TT-Maze: totally thoracoscopic maze 72 
  73 
Introduction 74 
Atrial fibrillation (AF) is a common condition with a prevalence around 3% in adults which is expected 75 
to rapidly increase in the next few decades.1–3 AF is an independent risk factor for stroke and rates are 76 
three to five-fold higher compared to the general population.1–3 The left atrial appendage (LAA) is 77 
thought to be the main source of stroke and emboli in AF patients and hence a variety of techniques 78 
have been developed to occlude or close this structure. Various surgical techniques have been 79 
described, such as suture ligation, stapling and surgical excision. However, these techniques often 80 
result in incomplete occlusion or residual pouches of the LAA that may contribute to thrombus 81 
formation and ongoing risk of stroke. 4,5,6  82 
 83 
A few small studies have shown promising results of LAA closure by using a clip during either open-84 
heart surgery 7 or thoracoscopic surgery. 8,9 In some centers, LAA clipping is routinely performed in 85 
combination with thoracoscopic AF ablation as part of the totally thoracoscopic maze procedure (TT-86 
maze).10,11 However, we currently lack systematic data about the efficacy of this procedure in terms of 87 
successful closure rates, or the safety of this approach. In this multicenter study, we evaluated both 88 
procedural success and complications of thoracoscopic clipping in consecutive patients undergoing 89 
either TT-maze or hybrid endocardial and epicardial ablation. The purpose of the study was to provide 90 
cardiologists, surgeons and the multidisciplinary AF care team with adequate information about this 91 
new technique. We hypothesize that thoracoscopic clipping would be an effective and durable 92 
approach for closure of the LAA. 93 
  94 
Methods 95 
This study has a prospective observational cohort design and was approved by the local ethical 96 
committee at the St. Antonius Hospital, Nieuwegein, the Catharina Hospital, Eindhoven, St. Helena 97 
Hospital, St. Helena and Sutter Medical Center, Sacramento (reference number: W15.077). 98 
 99 
Patient selection 100 
Consecutive patients who underwent thoracoscopic LAA clipping between February 2012 and March 101 
2016 in 4 major referral centers in the Netherlands and USA were included. All patients were suffering 102 
from symptomatic, drug-refractory AF and were discussed by the multidisciplinary AF care team (the 103 
AF Heart Team) consisting of dedicated cardiac surgeons and electrophysiologists.  104 
 105 
Study endpoints  106 
The primary outcome for this study was complete LAA closure defined as absence of residual flow in 107 
the LAA after clipping, combined with a residual LAA pouch of less than 10 mm revealed by either 108 
computed tomography (CT) or transesophageal echocardiography (TEE). CT and TEE were 109 
performed in all patients according to local operating procedures, approximately 6 months after 110 
surgery (some patients earlier or later depending on clinical need). Complete LAA closure also implied 111 
successful introduction of the clip into the chest cavity, positioning and release of the clip and removal 112 
of the steering tool. 113 
The secondary outcomes were: (1) 30-day freedom from complications; (2) freedom from the 114 
combined clinical endpoint of ischemic stroke, hemorrhagic stroke or transient ischemic attack (TIA); 115 
and (3) all-cause mortality. The following operative complications were classified as clip related: signs 116 
of cardiac ischemia and bleeding related to the introduction of the clip into the chest cavity, clip 117 
positioning and release, and conversion to (mini)thoracotomy or sternotomy.  118 
 119 
Data collection 120 
All patient data were prospectively gathered as each patient went through their surgery and hospital 121 
admission; we used medical and operative charts and records, including data on complications 122 
(surgical, bleeding and others) and medication usage (including prescription charts for anticoagulation 123 
and antiarrhythmic drug therapy). 124 
Complications after surgery were extracted from these records using a standardized list of potential 125 
complications.11 When patients were referred from other centers, these centers were contacted to 126 
assess if any complications from the standardized list occurred between discharge from our hospital 127 
and 30 days postoperatively. Survival data were obtained from hospital and national registry data.  128 
Stroke data and medication history at latest follow-up were obtained by telephone interviews with all 129 
individual patients. Patients were interviewed according to the Questionnaire for Verifying Stroke-Free 130 
Status.12 Additionally we contacted the neurologists at local hospitals to check for confirmation of any 131 
diagnosis of a cerebrovascular event. Neurologic events in this series were confirmed by MRI-scan 132 
according to local clinical protocols. 133 
 134 
Device 135 
Details of the clip (AtriClip™, AtriCure, Inc. Mason, Ohio, USA) have been described previously.13 In 136 
brief, the clip is composed of two parallel titanium crossbars covered with a woven polyester sheath. 137 
Nitinol springs at each end provides, dynamic, parallel pressure on the tissue causing tissue necrosis.  138 
The clip can be easily repositioned prior to being deployed if required. 139 
 140 
Surgical Procedure  141 
An extensive and video-guided description of the TT-maze has been published previously.10 In brief, 142 
the TT-maze consists of an epicardial pulmonary vein isolation with creation of a box through bilateral 143 
video-assisted thoracoscopic surgery using the AtriCure Isolator Synergy ablation clamp (AtriCure Inc) 144 
and the Cool rail pen (AtriCure Inc). The box is connected with the base of the LAA and furthermore 145 
with the left fibrous trigone. The endpoint of the ablation is sinus rhythm and bidirectional block 146 
confirmation of the pulmonary veins and box. Clipping of the LAA is performed in all patients 147 
immediately after ablation as a routine part of the TT-maze procedure. First, the length of the base of 148 
the LAA is measured with a sizer. The appropriate clip is then introduced and directed parallel to the 149 
base of the LAA. The clip is opened and manipulated over the LAA assisted by a blunt suction device. 150 
The clip is then closed after direct thoracoscopic confirmation of correct positioning fully against the 151 
LAA base. The clip is opened and repositioned in case of a suboptimal position and/or a residual 152 
pouch revealed by TEE or by direct thoracoscopic view. After conformation of an appropriate position 153 
of the clip, release of the clip from the steering tool is delayed for 30 seconds to rule out 154 
electrocardiographic ST-segment changes and wall motion disturbances on TEE.  155 
 156 
Postoperative care and follow-up  157 
Oral anticoagulation was initiated on the first postoperative day with either non-vitamin-K-dependent 158 
oral anticoagulants (NOAC), or vitamin-K-antagonists and low-molecular-weight heparin injections 159 
until an International Normalized Ratio level of ≥ 2 was achieved. The next day, anti-arrhythmic drugs 160 
were restarted depending on heart rate and rhythm. After discharge management of oral 161 
anticoagulation and anti-arrhythmic drugs were left to the discretion of the referring cardiologist.  162 
 163 
Computed tomography-scan 164 
CT-scans were performed according to the local protocol. A dual-source CT scanner system, 256-or 165 
356-slice CT scanner with non-ionic contrast medium was used. Three-dimensional reconstructions 166 
were created. The base of the LAA was defined as the line that starts 3 mm peripheral from the 167 
circumflex vein or artery on the coronal sections. From this point, an imaginary line is directed towards 168 
the sharp angle representing the border between the LAA and the epicardium. The distance between 169 
the mid part of this imaginary line and the clip, was systematically measured and defined as residual 170 
pouch length (Figure 1). All CT-scans were adjudicated by an independent radiologist (HWVE).  171 
 172 
Transesophageal echocardiography  173 
TEE imaging of the LAA was systematically performed by an independent cardiologist according to the 174 
local protocol. Starting with the high mid-oesophageal view at 0 degrees, followed by views at 45, 60, 175 
90 and 105 degrees from the top of the mitral valve annulus, with further views as necessary for 176 
optimal imaging, including a 3D and en-face view of the LAA orifice. 177 
 178 
Statistics 179 
Descriptive statistics were used to report patients' characteristics. Continuous variables were reported 180 
as mean ± standard deviation. Percentages were used to report categorical variables. The estimated 181 
event-free survival probabilities were calculated using Kaplan–Meier analysis. Data were analyzed 182 
using SPSS version 22 and Stata version 14.2. 183 
 184 
  185 
Results 186 
 187 
Patient characteristics 188 
Patient characteristics are outlined in Table 1. In total 222 patients were included in our analysis: St. 189 
Antonius Hospital (n=67, 2 operating surgeons), the Catharina Hospital (n=33, 1 operating surgeon), 190 
St. Helena Hospital (n=66, 1 operating surgeon) and Sutter Medical Center (n=56, 1 operating 191 
surgeon). 70.3% (n=156) underwent thoracoscopic LAA clipping as part of a standalone TT-maze and 192 
29.7% (n=66) as part of thoracoscopic procedure followed by a planned second stage catheter 193 
ablation (hybrid maze procedure including epicardial then endocardial ablation after 6 weeks). 194 
The mean age of the patients was 66±9 years and 68.5% (n=152) were male. Paroxysmal AF was 195 
present in 17.3% (n=38), persistent AF in 28.6% (n=63), longstanding persistent in 52.7% (n=116) and 196 
atypical atrial flutter in 1.4% (n=3). Mean arrhythmia duration prior to surgery was 8±8 years. Previous 197 
catheter ablation was performed in 45.5% (n=101) and a documented prior history of ischemic stroke 198 
was reported in 9.9% (n=22). Mild or moderate mitral regurgitation was present in 36.6% (n=81) and 199 
left ventricular ejection fraction < 50% in 23.5% (n=52). The mean CHA2DS2-VASc score was 2.3±1.5, 200 
the mean CHADS2 score was 1.3±1.1 and the median hospital stay was 4 days (interquartile range 3-201 
6 days).  No patients were lost to follow-up. 202 
 203 
Primary outcome 204 
Complete closure was achieved in 95.0% (211/222) as assessed with CT-scan or TEE after a median 205 
period of 6 months after the LAA clipping procedure (interquartile range 3-8 months).  206 
In those with a follow-up CT-scan, complete closure of the LAA was obtained in 93.0% (93/100). 207 
Absence of residual flow or contrast peripheral to the clip was confirmed in all patients. A residual 208 
pouch of more than 10 mm was present in 7 patients and the overall mean size of the residual pouch 209 
was 14±3 mm [range: 11-19 mm]. In 2 patients a residual pouch could not be measured because of 210 
poor quality of the CT-scan. In 1 patient the LAA was clipped partially and repositioning was not 211 
possible. Therefore a second clip was introduced and positioned over the first clip into an adequate 212 
position at the base of the LAA. 213 
In those patients with a follow-up TEE, complete closure of the LAA was obtained in 96.7% (118/122). 214 
Absence of residual flow peripheral to the clip was confirmed in all patients. A residual pouch of more 215 
than 10 mm was observed in 4 patients and the overall mean size of the pouch was 16±5 mm [range: 216 
10-21 mm]. 217 
 218 
Secondary outcomes 219 
Surgical complications: No intraoperative complications occurred and there were no clip-related 220 
complications seen. No patients died during 30-day follow-up.  Overall freedom from any 30-day 221 
complication was 96.4%. All complications that occurred are listed in Tables 2 and 3. The 30-day 222 
major complication rate was 0.9% (n=2) and minor complication rate was 4.5% (n=10). 223 
Cerebrovascular events: The freedom from the combined endpoint of ischemic stroke, hemorrhagic 224 
stroke or TIA was 99.1% over 369 patient-years of follow-up (median length of follow-up 20 months; 225 
interquartile range 14-25 months); Figure 2A. The observed cerebrovascular event rate was low at 0.5 226 
per 100 patient-years, with 57% of patients not on oral anticoagulation therapy at latest follow-up. In 227 
detail, one patient had an ischemic stroke confirmed on MRI 24 months after TT-maze (CHA2DS2-228 
VASc score 3, on oral anticoagulation therapy and in sinus rhythm at the time), and another patient 229 
had a TIA 30 months after TT-maze (CHA2DS2-VASc score 1 and off oral anticoagulation therapy).  230 
All-cause mortality: 3 patients died during median follow-up of 14 months (interquartile range 9-22 231 
months), all of non-cardiac causes; Figure 2B.  232 
 233 
  234 
Discussion 235 
Stroke prevention is one of the cornerstones of AF treatment. The LAA is the main source of thrombo-236 
embolism  in AF patients, due to blood stasis and coagulation, fulfilling the main conditions of 237 
Virchow’s triad.14–18 Oral anticoagulation is the mainstay of stroke prevention in AF, but other 238 
strategies are now available and can complement interventional approaches to rhythm control. This is 239 
the first observational multicenter cohort study evaluating procedural success and complications of 240 
thoracoscopic LAA clipping. We observed high LAA closure rates (95.0%), the absence of clip related 241 
complications, and a low rate of cerebrovascular events at 0.5 per 100 patient years. To put into 242 
context for a CHA2DS2-VASc score of 2 in large population databases, the event rate in non-243 
anticoagulated patients is approximately 2.0 per 100 patient years, 1.2 per 100 patient years for those 244 
with a similar rate of anticoagulation as observed in our cohort, and 0.7 per 100 patient years for those 245 
fully anticoagulated (Table 4). 19–22 246 
 247 
Surgical LAA closure 248 
Various surgical techniques of LAA closure have been described, such as suture ligation, stapling and 249 
surgical excision. These techniques are associated with incomplete LAA closure rates of 40-60%.5,6 250 
Depending on the morphology after incomplete closure, these remnant LAA may present an ongoing 251 
risk of thrombus formation and embolisation. 23,24 Our data on LAA clipping have shown a complete 252 
closure rate of 95.0% based on a large cohort of consecutive patients in 4 different referral centers, 253 
consistent with published data from a smaller single center cohort.25 Put together, these data suggest 254 
that thoracoscopic LAA clipping has overcome the problems of reproducibility seen in other surgical 255 
techniques. Interestingly, long-term follow-up data from LAA clipping in patients undergoing 256 
sternotomy showed stable closure rates of 100% after 5 years.7 We speculate that the closure rate in 257 
our patient group will also remain stable, since the clips used in our study were similar. 258 
The primary outcome in this study, complete closure rate, depends on the applied definition of 259 
complete closure. Earlier papers from LAA clipping randomly used a cut-off value of 10 mm for the 260 
definition of complete closure without a clear anatomic description of how the LAA pouch was 261 
assessed. 9,26,27 We therefore decided to accept the fairly liberal cut-off point of 10 mm as the second 262 
condition for the definition of complete closure. Absence of any contrast peripherally from the clip in all 263 
patients in this series seems to be a beneficial difference compared to significant (≥ 3-5 mm) or not-264 
significant (≤ 3-5 mm) peridevice leaks described for the percutaneous closure devices.  265 
 266 
Percutaneous transcatheter LAA occlusion 267 
Percutaneous transcatheter LAA occlusion, including the WATCHMAN device (Boston Scientific Inc, 268 
Marlborough, USA) the Amplatzer (St. Jude Medical, Minneapolis, USA) and the Lariat LAA exclusion 269 
system (SentreHeart Inc, Redwood City, California, USA) are associated with closure rates varying 270 
from 91-98.5%.28–34 However, the definition of success  included peri-device leakage of ≤ 3-5 mm in 271 
diameter for WATCHMAN and Amplatzer (8-13% of the patients 30,31,33) and  2 mm in diameter for 272 
Lariat (n=13, 1.8%).34 Although these remnant orifices are small, the clinical relevance is unknown and 273 
might possibly explain why the overall stroke rate after 5 years is non-inferior to warfarin therapy only. 274 
No comparison studies between percutaneous LAA closure and NOAC therapy are as yet available. 275 
Another potential challenge of percutaneous devices is the risk of device related thrombus.33 276 
The event rate for the composite endpoint of stroke and systemic embolism was 1.0% (mean CHADS2 277 
score 2.4) and 1.6% (mean CHADS2 score 2.2) per year for Lariat (SentreHeart Inc) and WATCHMAN 278 
(Boston Scientific Inc) respectively. 35,36  279 
Although the 30-day complication rate in our study (5.4%) was not directly clip related, it is in line with 280 
the device related complication rates described after percutaneous devices (8.7%) and Lariat 281 
implantation (5.3%).29,36,37 The recently published EWOLUTION trial showed a 30-day device and 282 
procedure-related complication rate of 3.6%, indicating a learning-curve effect for percutaneous 283 
devices,33 which is also likely to apply to thoracoscopic LAA clipping. In contrast to the WATCHMAN, 284 
Amplatzer and Lariat system which are all restricted to ostial size, LAA size or morphology, 285 
thoracoscopic LAA clipping is performed under direct view irrespective of LAA size, anatomy or atrial 286 
dilatation. 287 
 288 
Current guidelines 289 
Current guidelines suggest continuation of anticoagulation therapy in patients at risk for stroke after 290 
closure or exclusion of the LAA, even after successful ablation. 1 This can be explained by several 291 
reasons: that successful ablation does not guarantee maintenance of sinus rhythm, (recurrent) AF is 292 
often asymptomatic, and that the LAA is not the only source of stroke. Adequately powered 293 
randomized controlled trials investigating the effect of LAA closure on stroke reduction are not 294 
available, 38 and we await results from the Left Atrial Appendage Occlusion Study III (LAAOS III) 295 
comparing cardiac surgery with and without LAA closure in AF patients. However, many clinicians 296 
tend to stop anticoagulation therapy after successful ablation and/or closure or exclusion of the LAA 297 
despite elevated stroke risk. This approach can only be condoned after appropriate trials have 298 
demonstrated safety, in particular the comparison between LAA closure/exclusion and NOAC therapy.  299 
Even with anticoagulation, there is a residual risk of stroke in patients with AF that should be 300 
considered and discussed with patients.1,39  301 
 302 
Limitations 303 
Although this is the first multicenter study reporting on the efficacy and safety of LAA clipping, it is an 304 
observational study with potential risk of selection bias. As described in our methods section, patients 305 
eligible for TT-maze were first discussed and referred by the multidisciplinary AF care team. They are 306 
not representative of an ‘’average’’ AF population since 46% had prior catheter ablation. Furthermore, 307 
the low event rate of cerebrovascular events was likely multifactorial including not only the LAA clip, 308 
but also the effect of oral anticoagulation and rhythm control. Although we report on the number of 309 
patients taking anticoagulation at the end of follow-up, periods on and off anticoagulation, and the time 310 
in therapeutic range for those on vitamin-K-antagonists, was not collected. The follow-up time was 311 
relatively short and patient numbers limited, and therefore no definite conclusions regarding stroke 312 
reduction can be made. Although we provide a detailed overview of 30-day complications, long-term 313 
events (aside from cerebrovascular events and mortality) were not studied. 314 
 315 
Conclusion 316 
Thoracoscopic LAA clipping is a feasible and safe LAA closure approach with lower than expected 317 
rates of stroke after deployment. Randomized trials are required to directly compare this approach 318 
with and without cessation of NOAC therapy to assess the place of thoracoscopic LAA clipping for 319 
stroke prevention in AF. 320 
 321 
  322 
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  448 
Table 1. Patient characteristics 449 
Results Total 
N=222 
Age, years 66±9   
Male gender 152  (68.5%) 
Mean duration of AF, years 8±8  
Type of AF 
   Paroxysmal AF 
   Persistent AF 
   Longstanding persistent AF 
   Atrial flutter 
 
38 (17.3%) 
63 (28.6%) 
116 (52.7%) 
3 (1.4%) 
Left ventricular ejection fraction 
  > 50% 
  < 50% 
 
169 (76.5%) 
52 (23.5%) 
Mitral regurgitation 
  None 
  Trace 
  Mild 
  Moderate 
  Moderately severe 
 
65 (29.4%) 
74 (33.5%) 
61 (27.6%) 
20 (9.0%) 
1 (0.5%) 
CHA2DS2-VASc score 2.3±1   
CHADS2 score 1.2±1   
Prior catheter ablation 
 Of which > 1 procedure 
100 (45.5%) 
63 (28.8%) 
History of ischemic stroke 22 (9.9%) 
 450 
  451 
Table 2. Intraoperative complications 452 
 453 
Complication N (%) 
Mortality 0 (0.0) 
Stroke 0 (0.0) 
Sternotomy for bleeding 0 (0.0) 
Mini-sternotomy for bleeding 0 (0.0) 
Mini-thoracotomy for bleeding 0 (0.0) 
Bleeding with discontinuation of procedure 0 (0.0) 
Total number of intraoperative complications, n (%) 0 (0.0) 
 454 
Standardized reporting of intraoperative complications is presented according to published criteria.40 455 
  456 
Table 3. Postoperative complications 457 
Major N (%) 
Clip related complications 0 (0.0) 
Death 0 (0.0) 
Reinterventions*:  
  Hemothorax 
  Pericardial effusion/tamponade 
  Empyema 
 
0 (0.0) 
0 (0.0) 
1 (0.5) 
Re-intubation to hemodynamic instability 1 (0.5) 
Re-intubation without hemodynamic instability 0 (0.0) 
Venous lung Infarction 0 (0.0) 
Lung emboli 0 (0.0) 
Permanent phrenic nerve paralysis 0 (0.0) 
Stroke 0 (0.0) 
Transient Ischemic Attack 0 (0.0) 
Atrium-esophagus fistula 0 (0.0) 
Myocardial infarction 0 (0.0) 
Total number of patients with ≥1 major complication 2 (0.9) 
Total number of major complications  2 (0.9) 
Minor  
Pericardial fluid necessitating pericardiocentesis 0 (0.0) 
Permanent pacemaker implantation 2 (0.9) 
Thoracostomy drain for:  
  Pneumothorax 
 
0 (0.0) 
 458 
Standardized reporting of postoperative complications is presented according to published criteria.40 459 
*Including thoracotomy, sternotomy or Video-Assisted-Thoracoscopic Surgery.   460 
 461 
  Pleural effusion 
  Hematothorax 
3 (1.4) 
1 (0.5) 
Infections: 
  Airway infection 
  Urinary tract infection  
  Superficial wound infection 
 
1 (0.5) 
2 (0.9) 
0 (0.0) 
Delirium 1 (0.5) 
Gastrointestinal bleeding  0 (0.0) 
Total number of patients with ≥1  minor complication 8 (3.6) 
Total number of minor complications  10 (4.5) 
Overall freedom from 30-day complications 96.4% 
Table 4: Indirect comparison of events with a CHA2DS2-VASc score of 2 462 
Study 
Oral 
anticoagulation 
use (%) 
CHA2DS2-VASc Outcome 
Person-years 
of follow-up 
Rate per 100 
person-years Description study 
Nielsen21 0% 2 Ischemic stroke and systemic embolism 114,034 2.0 
Danish nationwide observational study of 
hospitalized AF patients not receiving 
anticoagulation 
Van de Ham22 0% 2 Ischemic stroke 21,500 1.9 
UK observational general practice electronic 
health record database of AF patients not 
receiving anticoagulation 
Allen et al20 43% 2 Ischemic stroke 37,750 1.2 
UK observational general practice electronic 
health record database of AF patients with 
and without anticoagulation 
THIS STUDY 43% Mean 2.3 Ischemic stroke and transient ischemic attack  369 0.5 
US and Netherlands observational study of 
patients undergoing LAA clipping during 
thoracoscopic AF ablation 
Yao et al19 100% 2 to 3 Ischemic stroke and systemic embolism 26,250 0.7 
US commercial insurance database of AF 
patients initiated on anticoagulation 
 463 
 
